Amgen Completes Acquisition of Horizon Therapeutics plc
October 6, 2023
Amgen completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction equity at approximately $27.8 billion. The deal expands Amgen’s inflammation and rare-disease portfolio by adding Horizon’s first-in-class, early-in-lifecycle medicines such as TEPEZZA, KRYSTEXXA, and UPLIZNA.
- Buyers
- Amgen
- Targets
- Horizon Therapeutics plc
- Industry
- Biotechnology
- Location
- United Kingdom
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.